Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 15:11:582106.
doi: 10.3389/fimmu.2020.582106. eCollection 2020.

Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment

Joshua R D Pearson  1   2 , Stefania Cuzzubbo  3   4 , Simon McArthur  5 , Lindy G Durrant  6 , Jason Adhikaree  7 , Chris J Tinsley  1   2 , A Graham Pockley  1   2 , Stephanie E B McArdle  1   2
Affiliations
Review

Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment

Joshua R D Pearson et al. Front Immunol. .

Abstract

Glioblastoma multiforme (GBM) is the most frequently occurring primary brain tumor and has a very poor prognosis, with only around 5% of patients surviving for a period of 5 years or more after diagnosis. Despite aggressive multimodal therapy, consisting mostly of a combination of surgery, radiotherapy, and temozolomide chemotherapy, tumors nearly always recur close to the site of resection. For the past 15 years, very little progress has been made with regards to improving patient survival. Although immunotherapy represents an attractive therapy modality due to the promising pre-clinical results observed, many of these potential immunotherapeutic approaches fail during clinical trials, and to date no immunotherapeutic treatments for GBM have been approved. As for many other difficult to treat cancers, GBM combines a lack of immunogenicity with few mutations and a highly immunosuppressive tumor microenvironment (TME). Unfortunately, both tumor and immune cells have been shown to contribute towards this immunosuppressive phenotype. In addition, current therapeutics also exacerbate this immunosuppression which might explain the failure of immunotherapy-based clinical trials in the GBM setting. Understanding how these mechanisms interact with one another, as well as how one can increase the anti-tumor immune response by addressing local immunosuppression will lead to better clinical results for immune-based therapeutics. Improving therapeutic delivery across the blood brain barrier also presents a challenge for immunotherapy and future therapies will need to consider this. This review highlights the immunosuppressive mechanisms employed by GBM cancers and examines potential immunotherapeutic treatments that can overcome these significant immunosuppressive hurdles.

Keywords: GBM - Glioblastoma multiforme; combinatorial therapy; immune escape; immunotherapy; overview; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overview of immunosuppressive mechanisms utilized by GBM tumors.
See this image and copyright information in PMC

References

    1. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol (2017) 19(suppl_5):v1–v88. 10.1093/neuonc/nox158 - DOI - PMC - PubMed
    1. Petrecca K, Guiot MC, Panet-Raymond V, Souhami L. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. J Neurooncol (2013) 111(1):19–23. 10.1007/s11060-012-0983-4 - DOI - PubMed
    1. Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amista P, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol (2009) 27(8):1275–9. 10.1200/JCO.2008.19.4969 - DOI - PubMed
    1. Sherriff J, Tamangani J, Senthil L, Cruickshank G, Spooner D, Jones B, et al. Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. Br J Radiol (2013) 86(1022):20120414. 10.1259/bjr.20120414 - DOI - PMC - PubMed
    1. Hadjipanayis CG, Stummer W. 5-ALA and FDA approval for glioma surgery. J Neurooncol (2019) 141(3):479–86. 10.1007/s11060-019-03098-y - DOI - PMC - PubMed

Publication types